XML 44 R36.htm IDEA: XBRL DOCUMENT v3.22.2
Collaborations - Summary of Company's Collaboration Arrangements Earned in Period to Be Billed and Collected in Next Period (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses:        
Research and development $ 31,096 $ 24,612 $ 58,071 $ 45,418
General and administrative 12,695 10,569 24,448 19,902
Total operating expenses 43,791 35,181 82,519 65,320
Incyte        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payments (4,230) (4,791) (8,632) (9,525)
Reimbursement revenue 2,250 2,470 4,214 4,487
Milestones 1,000   1,000  
Other 0   0  
Total collaboration revenue 7,480 7,261 13,846 14,012
Operating expenses:        
Research and development 182 289 550 648
General and administrative 0   0  
Total operating expenses 182 289 550 648
Revenue recognized in the period 4,230 4,791 8,632 9,525
Lilly        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payments (4,147) (3,765) (8,185) (4,911)
Reimbursement revenue 1,057 869 2,036 1,132
Milestones 0   0  
Other 0   0  
Total collaboration revenue 5,204 4,634 10,221 6,043
Operating expenses:        
Research and development 0 0 0  
General and administrative 0   0  
Total operating expenses 0   0  
Revenue recognized in the period 4,147 3,765 8,185  
Other        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payments (0) (162) (222) (352)
Reimbursement revenue 0 322 0 322
Milestones 0   0  
Other 0   50  
Total collaboration revenue 0 484 272 674
Operating expenses:        
Research and development 0 0 0  
General and administrative 0   0  
Total operating expenses 0   0  
Revenue recognized in the period 0 162 222 352
Collaboration Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Upfront payments (8,377) (3,927) (17,039) (5,263)
Reimbursement revenue 3,307 1,191 6,250 1,454
Milestones 1,000   1,000  
Other 0   50  
Total collaboration revenue 12,684 5,118 24,339 6,717
Operating expenses:        
Research and development 182 0 550  
General and administrative 0   0  
Total operating expenses 182   550  
Revenue recognized in the period $ 8,377 $ 3,927 $ 17,039 $ 352